Saltz:
Well done and on point. However much of this nonsense and hand to mouth funding will be a distant memory when we up list- which could come sooner rather than later if management would consider a miniscule 1/2 RS once we're on solid footing in $2.00- $2.25 range. The NASDAQ is heaven sent for non revenue biotech companies and would love to see us at $4.00+ when the jump is made.
Companies ( and this was in a quick 15 minute search) like AXSM, KOD, CNST,XBIT,CUE,PRVB, BTAI - etc all spiked from low ends $2.00-$4.00 to as high as $110 in past year with ZERO revenue and operating losses ranging from $24 million to $64 million- Things they had in common are low O/S between 23 million to 64 million and institutional ownership ranging from 22% to 85% -
Can't imagine a more compelling or exciting story than Leronlimab has to tell/sell, but it would be prudent to halve ( at least) the current outstanding shares. I'll set aside my opinion of NP's bodacious outbursts and hope that we'll be leaving the swamp for Shangri La ASAP-